QIAGEN Introduces Novel Technology for Customized RNAi Assay Products

Share This.....Share on LinkedInTweet about this on TwitterShare on FacebookShare on Google+Email this to someone
    VENLO, The Netherlands, November 13 /PRNewswire-FirstCall/ --
     - Worldwide First Solution for Flexible siRNA Selection Provides New
 Dimension of Utility and Performance in one of Life Sciences' Most
 Promising Disciplines
     QIAGEN, (Nasdaq:   QGEN; Frankfurt, Prime Standard: QIA) the world's
 leading provider of products for pre-analytical sample preparation and a
 leader in molecular diagnostics, has introduced FlexiPlate siRNA, the
 worldwide first product line for fully customized sets of siRNAs for RNA
 Interference (RNAi) research.
     Small interfering RNAs (siRNAs) are little RNA molecules which silence
 specific genes by inhibiting their expression. RNAi and the ability to
 knockdown any gene is expected to create new benefits in the future
 development of science and therapeutics. This year's Nobel Prize in
 Medicine was awarded to Craig C. Mello and Andrew Z. Fire for research in
 the field of RNAi.
     Previously, biologists had to rely on pre-defined sets of siRNAs. Now
 QIAGEN's novel FlexiPlate siRNA ensures a new dimension of flexibility by
 allowing users to determine not only the exact RNAi assay, but also exactly
 the amount of siRNAs needed for their individual requirements. These
 advantages directly result in significant cost savings in RNAi projects.
     Efficient processing allows screening of more targets, hence more RNAi
 projects can be completed. In high throughput RNAi-based screening,
 Flexiplate is expected to lead to faster, less expensive and more specific
 research. In low throughput RNAi, FlexiPlate allows customers to quantify
 the number of RNAi assays needed, thereby often leading to the ability to
 use 7 times as many assays when compared to unquantified offerings.
     Customers can select and order any set of siRNAs interactively via
 QIAGEN's GeneGlobe web portal which hosts the world's largest database of
 matching siRNA assays for all human and mouse genes as well as the
 corresponding gene expression assays. The selected siRNA sets are then
 quickly delivered in standard 96-well plates, which allow direct processing
 by customers.
     "The new FlexiPlate siRNA product line provides a dramatic step forward
 for research applying RNAi. It expands QIAGEN's already broad portfolio of
 RNAi solutions and capabilities and demonstrates the company's well
 established and expanding leadership in this field," said Dr. Bettina
 Haedrich, Global Product Manager RNAi at QIAGEN. In 2005 QIAGEN launched
 the worldwide first human whole genome siRNA set, followed this year by the
 world's first siRNA sets for whole mouse genome. "Most researchers know the
 problem of having too much siRNA or too many siRNAs for their experiments.
 With FlexiPlate siRNAs and GeneGlobe technology, they find now an effective
 tool which makes their RNA screening more flexible, economical and
 convenient," Dr. Haedrich added.
     About RNAi and siRNA:
     RNAi is a mechanism in molecular biology to "silence" genes by
 preventing the formation (or expression) of the proteins which those genes
 code for. The expression is inhibited by the introduction of little RNA
 molecules into the cell. These so-called small interfering RNAs (siRNAs)
 bind to and destroy their messenger RNA targets (mRNA), preventing the
 synthesis of final proteins, which - for instance - could account for
 certain diseases. Market estimates show that the global RNAi market could
 grow annually up to 30 percent, accumulating US$ 330 million in worldwide
 revenues by 2010. QIAGEN believes it is the market and technology leader in
 RNAi products used in pharmaceutical research.
     Milestones in QIAGEN's Leadership as a supplier of RNAi:
 
     2006    Worldwide first mouse whole genome siRNA set
             Fully validated human kinase siRNA set
     2005    Worldwide first human whole genome siRNA set
             Matching RNAi & qRT-PCR assays: Gene Globe
             Developed superior HiPerfect Transfection Reagent
     2004    Exclusively licensed neural network design for RNAi from Novartis
             First whole genome human library set
     2003    First purification methods that allows HTS synthesis
             First human druggable genome siRNA set
     2002    World-wide first RNAi library set for cancer
 
 
     About QIAGEN:
     QIAGEN N.V., a Netherlands holding company, is a leading provider of
 innovative technologies and products for pre-analytical sample preparation
 and molecular diagnostics solutions. QIAGEN has developed a comprehensive
 portfolio of more than 500 proprietary, consumable products and automated
 solutions for sample collection, and nucleic acid and protein handling,
 separation, and purification. QIAGEN also supplies diagnostic kits, tests,
 and assays for human and veterinary molecular diagnostics. The company's
 products are sold to academic research markets, and to leading
 pharmaceutical and biotechnology companies; as well as to diagnostics
 laboratories. QIAGEN also provides purification and testing solutions to
 applied testing markets: such as forensics, animal or food testing, and
 pharmaceutical process control.
     QIAGEN employs more than 1,800 people worldwide. QIAGEN products are
 sold through a dedicated sales force and a global network of distributors
 in more than 40 countries.
     Further information about QIAGEN can be found at www.qiagen.com.
     Certain of the statements contained in this news release may be
 considered forward-looking statements within the meaning of Section 27A of
 the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S.
 Securities Exchange Act of 1934, as amended. To the extent that any of the
 statements contained herein relating to QIAGEN's products, markets,
 strategy or operating results are forward-looking, such statements are
 based on current expectations that involve a number of uncertainties and
 risks. Such uncertainties and risks include, but are not limited to, risks
 associated with management of growth and international operations
 (including the effects of currency fluctuations and risks of dependency on
 logistics), variability of operating results, the commercial development of
 the applied testing markets, clinical research markets and proteomics
 markets, nucleic acid-based molecular diagnostics market, and genetic
 vaccination and gene therapy markets, competition, rapid or unexpected
 changes in technologies, fluctuations in demand for QIAGEN's, products
 (including fluctuations due to the level and timing of customers' funding,
 budgets, and other factors), difficulties in successfully adapting QIAGEN's
 products to integrated solutions and producing such products, the ability
 of QIAGEN to identify and develop new products and to differentiate its
 products from competitors' products, market acceptance of QIAGEN's new
 products, the integration of acquisitions of technologies and businesses,
 and the timing of product introductions by our commercial partners. For
 further information, refer to the discussions in reports that QIAGEN has
 filed with, or furnished to, the U.S. Securities and Exchange Commission
 (SEC).
     Website: http://www.qiagen.com/Geneglobe

SOURCE QIAGEN NV


    VENLO, The Netherlands, November 13 /PRNewswire-FirstCall/ --
     - Worldwide First Solution for Flexible siRNA Selection Provides New
 Dimension of Utility and Performance in one of Life Sciences' Most
 Promising Disciplines
     QIAGEN, (Nasdaq:   QGEN; Frankfurt, Prime Standard: QIA) the world's
 leading provider of products for pre-analytical sample preparation and a
 leader in molecular diagnostics, has introduced FlexiPlate siRNA, the
 worldwide first product line for fully customized sets of siRNAs for RNA
 Interference (RNAi) research.
     Small interfering RNAs (siRNAs) are little RNA molecules which silence
 specific genes by inhibiting their expression. RNAi and the ability to
 knockdown any gene is expected to create new benefits in the future
 development of science and therapeutics. This year's Nobel Prize in
 Medicine was awarded to Craig C. Mello and Andrew Z. Fire for research in
 the field of RNAi.
     Previously, biologists had to rely on pre-defined sets of siRNAs. Now
 QIAGEN's novel FlexiPlate siRNA ensures a new dimension of flexibility by
 allowing users to determine not only the exact RNAi assay, but also exactly
 the amount of siRNAs needed for their individual requirements. These
 advantages directly result in significant cost savings in RNAi projects.
     Efficient processing allows screening of more targets, hence more RNAi
 projects can be completed. In high throughput RNAi-based screening,
 Flexiplate is expected to lead to faster, less expensive and more specific
 research. In low throughput RNAi, FlexiPlate allows customers to quantify
 the number of RNAi assays needed, thereby often leading to the ability to
 use 7 times as many assays when compared to unquantified offerings.
     Customers can select and order any set of siRNAs interactively via
 QIAGEN's GeneGlobe web portal which hosts the world's largest database of
 matching siRNA assays for all human and mouse genes as well as the
 corresponding gene expression assays. The selected siRNA sets are then
 quickly delivered in standard 96-well plates, which allow direct processing
 by customers.
     "The new FlexiPlate siRNA product line provides a dramatic step forward
 for research applying RNAi. It expands QIAGEN's already broad portfolio of
 RNAi solutions and capabilities and demonstrates the company's well
 established and expanding leadership in this field," said Dr. Bettina
 Haedrich, Global Product Manager RNAi at QIAGEN. In 2005 QIAGEN launched
 the worldwide first human whole genome siRNA set, followed this year by the
 world's first siRNA sets for whole mouse genome. "Most researchers know the
 problem of having too much siRNA or too many siRNAs for their experiments.
 With FlexiPlate siRNAs and GeneGlobe technology, they find now an effective
 tool which makes their RNA screening more flexible, economical and
 convenient," Dr. Haedrich added.
     About RNAi and siRNA:
     RNAi is a mechanism in molecular biology to "silence" genes by
 preventing the formation (or expression) of the proteins which those genes
 code for. The expression is inhibited by the introduction of little RNA
 molecules into the cell. These so-called small interfering RNAs (siRNAs)
 bind to and destroy their messenger RNA targets (mRNA), preventing the
 synthesis of final proteins, which - for instance - could account for
 certain diseases. Market estimates show that the global RNAi market could
 grow annually up to 30 percent, accumulating US$ 330 million in worldwide
 revenues by 2010. QIAGEN believes it is the market and technology leader in
 RNAi products used in pharmaceutical research.
     Milestones in QIAGEN's Leadership as a supplier of RNAi:
 
     2006    Worldwide first mouse whole genome siRNA set
             Fully validated human kinase siRNA set
     2005    Worldwide first human whole genome siRNA set
             Matching RNAi & qRT-PCR assays: Gene Globe
             Developed superior HiPerfect Transfection Reagent
     2004    Exclusively licensed neural network design for RNAi from Novartis
             First whole genome human library set
     2003    First purification methods that allows HTS synthesis
             First human druggable genome siRNA set
     2002    World-wide first RNAi library set for cancer
 
 
     About QIAGEN:
     QIAGEN N.V., a Netherlands holding company, is a leading provider of
 innovative technologies and products for pre-analytical sample preparation
 and molecular diagnostics solutions. QIAGEN has developed a comprehensive
 portfolio of more than 500 proprietary, consumable products and automated
 solutions for sample collection, and nucleic acid and protein handling,
 separation, and purification. QIAGEN also supplies diagnostic kits, tests,
 and assays for human and veterinary molecular diagnostics. The company's
 products are sold to academic research markets, and to leading
 pharmaceutical and biotechnology companies; as well as to diagnostics
 laboratories. QIAGEN also provides purification and testing solutions to
 applied testing markets: such as forensics, animal or food testing, and
 pharmaceutical process control.
     QIAGEN employs more than 1,800 people worldwide. QIAGEN products are
 sold through a dedicated sales force and a global network of distributors
 in more than 40 countries.
     Further information about QIAGEN can be found at www.qiagen.com.
     Certain of the statements contained in this news release may be
 considered forward-looking statements within the meaning of Section 27A of
 the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S.
 Securities Exchange Act of 1934, as amended. To the extent that any of the
 statements contained herein relating to QIAGEN's products, markets,
 strategy or operating results are forward-looking, such statements are
 based on current expectations that involve a number of uncertainties and
 risks. Such uncertainties and risks include, but are not limited to, risks
 associated with management of growth and international operations
 (including the effects of currency fluctuations and risks of dependency on
 logistics), variability of operating results, the commercial development of
 the applied testing markets, clinical research markets and proteomics
 markets, nucleic acid-based molecular diagnostics market, and genetic
 vaccination and gene therapy markets, competition, rapid or unexpected
 changes in technologies, fluctuations in demand for QIAGEN's, products
 (including fluctuations due to the level and timing of customers' funding,
 budgets, and other factors), difficulties in successfully adapting QIAGEN's
 products to integrated solutions and producing such products, the ability
 of QIAGEN to identify and develop new products and to differentiate its
 products from competitors' products, market acceptance of QIAGEN's new
 products, the integration of acquisitions of technologies and businesses,
 and the timing of product introductions by our commercial partners. For
 further information, refer to the discussions in reports that QIAGEN has
 filed with, or furnished to, the U.S. Securities and Exchange Commission
 (SEC).
     Website: http://www.qiagen.com/Geneglobe
 
 SOURCE QIAGEN NV